213261-59-7 | 5,5'-(2,5-FURANDIYL)BIS-2-THIOPHENEMETHANOL

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$50.00	$35.00
2mg	98%	in stock	$69.00	$48.00
5mg	98%	in stock	$90.00	$63.00
10mg	98%	in stock	$116.00	$81.00
100mg	98%	in stock	$269.00	$188.00
250mg	98%	in stock	$469.00	$328.00
1g	98%	in stock	$1,222.00	$855.00

Description

• Catalog Number: AF31550
• Chemical Name: 5,5'-(2,5-FURANDIYL)BIS-2-THIOPHENEMETHANOL
• CAS Number: 213261-59-7
• Molecular Formula: C14H12O3S2
• Molecular Weight: 292.3733
• MDL Number: MFCD03235294
• SMILES: OCc1ccc(s1)c1ccc(o1)c1ccc(s1)CO
• NSC Number: 652287

Computed Properties

• Complexity: 274
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 2

Literature

• Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

  Molecular cancer therapeutics 20121001

• Chk2 mediates RITA-induced apoptosis.

  Cell death and differentiation 20120601

• Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

  Cell death & disease 20120401

• Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.

  Oncogene 20120301

• Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.

  Biochemical and biophysical research communications 20120120

• Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.

  PloS one 20120101

• Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1.

  Cell death & disease 20110501

• p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.

  Oral oncology 20110101

• HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

  Cancer research 20090801

• Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells.

  Molecular pharmaceutics 20081006

• Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

  British journal of haematology 20080501

• Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

  International journal of pharmaceutics 20080303

• The ubiquitin system, disease, and drug discovery.

  BMC biochemistry 20080101

• Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.

  Theoretical biology & medical modelling 20050101

• Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

  Nature medicine 20041201

• Identification of the major metabolite of 2,5-bis(5-hydroxymethyl-2-thienyl)furan (NSC 652287), an antitumor agent, in the S9 subcellular fraction of dog liver cells.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020205